![Bo Jesper Hansen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Bo Jesper Hansen
Voorzitter bij Innoventa Medica ApS
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Viktor Drvota | M | 59 |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 9 jaar |
Niels Erik Holm | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | 16 jaar |
Annette Clancy | F | 70 | 10 jaar | |
Varun Gupta | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 6 jaar |
Rasmus Lundquist | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | 16 jaar |
Marianne Mertens | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 6 jaar |
Elisabet Gimbringer | F | 59 | 9 jaar | |
Claire Thomas | M | 68 | 8 jaar | |
Jakob Bendtsen | M | 46 | 1 jaar | |
Rainer Strohmenger | M | 57 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 27 jaar |
Rolf Christof Dienst | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 33 jaar |
Johannes Fischer | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 4 jaar |
Eric Archambeau | M | 66 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 18 jaar |
Filippo Moriggia | M | - | 8 jaar | |
Helena Ildiko Saxon | F | 54 | 13 jaar | |
Gitte Nøhr Ludvig | F | - |
Azanta A/S
![]() Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | 4 jaar |
Arturo Urrios | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 5 jaar |
Erik Niklas Eriksson | M | - |
Azanta A/S
![]() Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | 4 jaar |
Michael Elliott | M | - | 8 jaar | |
Michael Shlomo Hove | M | 53 | 1 jaar | |
Jakob Have | M | 43 | 1 jaar | |
Christine Wesström | F | 49 | 14 jaar | |
Wolfgang Baiker | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 8 jaar |
Samuel G. Levy | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Arthur Levin | M | 70 |
Amylon Therapeutics BV
![]() Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | - |
Cyrille Yann Nicolas Petit | M | 54 |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Christian Reitberger | M | 56 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 16 jaar |
Stuart Essig | M | 62 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 11 jaar |
Domenico Valerio | M | 67 |
Amylon Therapeutics BV
![]() Amylon Therapeutics BV Pharmaceuticals: MajorHealth Technology Amylon Therapeutics BV is a biopharmaceutical company, which engages in the research and development of therapies for the central nervous system. It specializes in ribonucleic acid modulation technology to target rare genetic disorders. The company was founded by Thomas de Vlaam and is headquartered in Leiden, the Netherlands. | 7 jaar |
Jørgen Ulrik Vejlsgaard | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Melvin Spigelman | M | 75 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 19 jaar |
Ulrik Spork | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Regina Hodits | M | 53 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 14 jaar |
Frank Böhnke | M | 61 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 26 jaar |
Harald Keller | M | - |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 26 jaar |
Erich Schlick | M | 72 |
Wellington Partners GmbH
![]() Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | 19 jaar |
Tonni Bülow-Nielsen | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Dennis Dionne | M | - | 9 jaar | |
Graeme Brookes | M | - |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | 10 jaar |
Klaus Eldrup-Jørgensen | M | 65 |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Søren Møller | M | 56 |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Richard Michael Twomey | M | 60 |
Reapplix A/S
![]() Reapplix A/S Medical DistributorsDistribution Services Reapplix A/S specializes in the biological treatment and management of diabetic foot ulcers. It develops the LeucoPatch device, which is composed of precision molded medical grade plastic components, that facilitates a processing of autologous blood. The company was founded by Niels Erik Holm and Rasmus Lundquist in 2008 and is headquartered in Birkerod, Denmark. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Anders Fink Vadsholt | M | 55 | 7 jaar | |
Craig A. Dionne | M | 67 | 13 jaar | |
Alf Gunnar Martin Nicklasson | M | 69 |
Swedish Orphan International Holding AB
![]() Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets.
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 3 jaar |
Jim van Heusden | M | 53 |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 2 jaar |
Christopher Lowe | M | 56 | 2 jaar | |
Terje Kalland | M | 73 |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 4 jaar |
Ashley C. Gould | F | 49 | - | |
Håkan Åström | M | 77 | 9 jaar | |
Thomas Jensen | M | 47 | 13 jaar | |
Erling Lennart Johansson | M | 69 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | - |
Peter John Fellner | M | 80 | 5 jaar | |
Donald Santel | M | 62 | 8 jaar | |
Adine Charlotte Grate Axén | F | 63 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | - |
Peter E. Grebow | M | 77 | 6 jaar | |
Nancy Jean Barnabei | F | 61 | 1 jaar | |
Wills Hughes-Wilson | F | 53 | 6 jaar | |
Wenche Nelly A. Rolfsen Sandsborg | M | 72 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 8 jaar |
Niclas Adler | M | 53 | - | |
Kennet Rooth | M | 69 |
Swedish Orphan International Holding AB
![]() Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Swedish Orphan International Holding AB is an international group with its head office in Stockholm, Sweden. The original company was formed in 1988, taking as its starting point the US Orphan Drug Act of 1983. In 2004, the company was acquired by a consortium consisting of Investor Growth Capital, Skandia Investment and the management of Swedish Orphan International AB. The operating companies are Swedish Orphan International and its subsidiaries in Europe and Japan. The organizational structure is primarily based on a logistical perspective. In order to reach patients in emergency situations, regardless of where they are, it needs an extensive organization with strong local roots and the ability to see things in a larger perspective. The better and broader its partnerships, the more effectively the firm can work and the greater the synergies that it can achieve between the various markets. | 5 jaar |
Catherine Moukheibir | F | 64 | 4 jaar | |
Hanne Damgaard Jensen | F | - |
Azanta A/S
![]() Azanta A/S Pharmaceuticals: MajorHealth Technology Azanta A/S develops pharmaceutical drugs for medical treatments in women´s health, oncology and addiction medicine. Its products include Angusta, which helps in cervical ripening and induction of labor. The firm also develops drugs for the treatment of head and neck cancer patients undergoing with radiotherapy. The company was founded by Claus Juan Møller-San Pedro and Jan Andersen in 1994 and is headquartered in Valby, Denmark. | 8 jaar |
Henrijette Richter | M | 53 | 3 jaar | |
William John Jenkins | M | 77 | - | |
Anders Hinsby | M | 51 | 10 jaar | |
Johannes G. C. P. Schikan | M | 66 | 9 jaar | |
Erik Kinnman | M | 66 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 3 jaar |
Peter Sellei | M | 64 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 1 jaar |
Martin N. Bonde | M | 61 | 12 jaar | |
Rune Fransson | M | 77 | 8 jaar | |
Karsten Witt | M | 68 | - | |
Thomas Kudsk Larsen | M | 50 | 2 jaar | |
Klaus K. Wilgenbus | M | 62 | 2 jaar | |
Theresa Heggie | F | 63 | 1 jaar | |
Richard Buller | M | 74 | 2 jaar | |
Cameron McDonough | M | 53 | 6 jaar | |
Per-Olof Edin | M | 84 | 7 jaar | |
Guido Oelkers | M | 59 |
Gambro AB
![]() Gambro AB Medical SpecialtiesHealth Technology Gambro AB engages in the development and manufacturing of dialysis equipment and blood purification products. It provides products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients. The firm offers products for hemodialysis, acute care, myeloma kidney therapy, and vascular access and water systems. The company was founded by Holger Crafoord in 1964 and is headquartered in Lund, Sweden. | 2 jaar |
Torbjørn Bjerke | M | 61 |
Karolinska Development AB (Private Equity)
![]() Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna. | 4 jaar |
Christopher Rivera | M | 63 | 9 jaar | |
Timothy Walbert | M | 57 | - | |
Michael Steinmetz | M | 75 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 10 jaar |
James Healy | M | 59 | 9 jaar | |
David Gryska | M | 68 | 4 jaar | |
Thomas Heinrich Glanzmann | M | 65 |
Gambro AB
![]() Gambro AB Medical SpecialtiesHealth Technology Gambro AB engages in the development and manufacturing of dialysis equipment and blood purification products. It provides products and therapies for kidney and liver dialysis, myeloma kidney therapy, and other extracorporeal therapies for chronic and acute patients. The firm offers products for hemodialysis, acute care, myeloma kidney therapy, and vascular access and water systems. The company was founded by Holger Crafoord in 1964 and is headquartered in Lund, Sweden. | 5 jaar |
Lutgart A. A. van den Berghe | M | 72 | - | |
Joseph deBethizy | M | 74 | 9 jaar | |
Hilde Windels | F | 59 | 1 jaar | |
Paul Hoelscher | M | 59 | - | |
Hans Glemstedt | M | 62 |
Biovitrum AB
![]() Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | 2 jaar |
Klara Dickinson-Eason | F | 57 | 7 jaar | |
Paula Treutiger | F | 57 | 3 jaar | |
John Farah | M | 72 | 2 jaar | |
Sten Verland | M | 67 | - | |
Carl Johan Bertil Sundberg | M | 66 | 3 jaar | |
Gunnar Magnus Modee Persson | M | 64 | 3 jaar | |
Lota Zoth | F | 64 | 7 jaar | |
Karl Härfstrand | M | 67 | 2 jaar | |
Andrew Paul Mercieca | M | 58 | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Zweden | 34 | 34.00% |
Denemarken | 26 | 26.00% |
Verenigde Staten | 17 | 17.00% |
Duitsland | 15 | 15.00% |
België | 4 | 4.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Bo Jesper Hansen
- Persoonlijk netwerk